Tuesday, February 08, 2011 3:08:03 PM
Rumor: Market talk that TEVA is interested in Momenta Pharma (MNTA) for $21 per share. (RANsquawk)
seekingalpha.com/article/251519-deal-watch-after-huffpo-are-gawker-and-business-insider-next-media-targets?source=yahoo
FWIW
From Dew:
LOL
Actually, I could see TEVA exploring such a thing. While the FTC would no doubt disallow TEVA from "cornering the market" on generic versions of enox (and Copaxone?), could you imagine the value of MNTA's technology to a company like TEVA? TEVA nakes great money off of its generics, right? What would absorbing MNTA do except accelerate its ability to do so?
Certainly there would be obstacles to such an acquisition, but TEVA would be in a far stronger position as a manufacturer of generics, wouldn't they?
Am I all wet? If so, please enlighten me.
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
